Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. COEP
stocks logo

COEP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q2
FY2024Q3
FY2024Q4
--
--
-1.800
+1416.43%
--
--
-1.000
-78.26%
--
--
-0.800
-39.7%
Estimates Revision
The market is revising No Change the revenue expectations for Coeptis Therapeutics Holdings, Inc. (COEP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 33.82%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+33.82%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Coeptis Therapeutics Holdings Inc (COEP.O) is -4.83, compared to its 5-year average forward P/E of -16.84. For a more detailed relative valuation and DCF analysis to assess Coeptis Therapeutics Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.84
Current PE
-4.83
Overvalued PE
22.02
Undervalued PE
-55.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.34
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.30
Undervalued EV/EBITDA
-4.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.43
Current PS
0.00
Overvalued PS
14.97
Undervalued PS
-6.10
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

COEP News & Events

Events Timeline

(ET)
2025-07-22
08:38:38
Coeptis Therapeutics extinguishes convertible note
select
2025-06-26 (ET)
2025-06-26
08:37:23
Coeptis files registration statement for proposed Z Squared transaction
select
2025-05-28 (ET)
2025-05-28
08:29:40
Monarch Therapeutics, SNAP Biosciences enter licensing agreement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
10-07Globenewswire
SHAREHOLDER RIGHTS NOTICE: Halper Sadeh LLC Probes BFIN, COEP, ARIS, CIO for Shareholder Interests

  • Investigation of Companies: Halper Sadeh LLC is investigating BankFinancial Corporation, Coeptis Therapeutics Holdings, Aris Water Solutions, and City Office REIT for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions.

  • Legal Rights for Shareholders: Shareholders of the mentioned companies are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options, with the firm offering services on a contingent fee basis, meaning no upfront costs for legal fees.

[object Object]
Preview
7.0
10-07Globenewswire
URGENT: M&A Class Action Firm Ongoing Investigation into the Merger Involving BFIN, ARIS, CIO, and COEP

  • Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.

  • Ongoing Investigations: The firm is currently investigating several companies, including BankFinancial Corporation, Aris Water Solutions, City Office REIT, and Coeptis Therapeutics, regarding their proposed mergers and sales, with shareholder votes scheduled for October 2025.

[object Object]
Preview
7.0
08-28PRnewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CYBR, UNP, COEP on Behalf of Shareholders

  • Investigation Announcement: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to several companies, including CyberArk Software Ltd., Union Pacific Corporation, and Coeptis Therapeutics Holdings, Inc.

  • CyberArk Software Details: The investigation focuses on CyberArk's sale to Palo Alto Networks, which involves a cash payment and shares of Palo Alto common stock for each CyberArk share.

  • Union Pacific and Coeptis Mergers: The firm is also looking into Union Pacific's merger with Norfolk Southern and Coeptis' merger with Z Squared, assessing shareholder rights and options.

  • Legal Support Offered: Halper Sadeh LLC offers legal assistance on a contingent fee basis, encouraging shareholders to contact them for free consultations regarding their legal rights and potential actions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Coeptis Therapeutics Holdings Inc (COEP) stock price today?

The current price of COEP is 16.42 USD — it has increased 3.14 % in the last trading day.

arrow icon

What is Coeptis Therapeutics Holdings Inc (COEP)'s business?

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

arrow icon

What is the price predicton of COEP Stock?

Wall Street analysts forecast COEP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for COEP is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Coeptis Therapeutics Holdings Inc (COEP)'s revenue for the last quarter?

Coeptis Therapeutics Holdings Inc revenue for the last quarter amounts to 237.44K USD, decreased % YoY.

arrow icon

What is Coeptis Therapeutics Holdings Inc (COEP)'s earnings per share (EPS) for the last quarter?

Coeptis Therapeutics Holdings Inc. EPS for the last quarter amounts to -0.58 USD, decreased -33.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Coeptis Therapeutics Holdings Inc (COEP)'s fundamentals?

The market is revising No Change the revenue expectations for Coeptis Therapeutics Holdings, Inc. (COEP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 33.82%.
arrow icon

How many employees does Coeptis Therapeutics Holdings Inc (COEP). have?

Coeptis Therapeutics Holdings Inc (COEP) has 5 emplpoyees as of December 05 2025.

arrow icon

What is Coeptis Therapeutics Holdings Inc (COEP) market cap?

Today COEP has the market capitalization of 88.97M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free